Fingerprints could replace needles for drug testing
NCT ID NCT07650136
First seen Jun 26, 2026 · Last updated Aug 04, 2026 · Updated 3 times
Summary
This study evaluates a new device that detects codeine in fingerprint sweat. Researchers will compare its accuracy to standard lab methods. 144 healthy adults will provide fingerprints after taking codeine. The goal is to see if this quick, non-invasive method works reliably for drug screening.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- codeine (measured in fingerprint sweat)
- What this could lead to
- If successful, this could provide a faster, less invasive way to screen for drug use using fingerprints instead of blood or urine.
- What could go wrong
- This is an early-stage device study focused on accuracy, not a treatment. It only tests for codeine, so results may not apply to other drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 144 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2026
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
135 "donors" and nine "operators." "Operators" represent end users who utilize the screening system in an office or work setting. These subjects do not have to possess special training in laboratory methods. "Donors" represent end users either applying for employment or working at an organization that conducts pre-employment and/or periodic workplace drug screening. Sufficient numbers of subjects will be screened to attain those numbers and to ensure that at least 33% of each sex and at least 15% Black subjects are included as "donors" in the study. At least two sites will have both sexes represented among "operator" subjects. Sites may recruit sufficient alternate subjects to ensure achievement of those numbers. Subjects will be selected from members of the community at large.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1\. Able to provide informed consent 2. Completed the screening process within 30 days prior to dosing. 3. Healthy male and non-pregnant female subjects at the time of dosing. 4. Body mass index (BMI) from 18.0 kg/m2 to 32.0 kg/m2, inclusive 5. Weigh at least 60 kg. 5. Females of childbearing potential must be willing to practice an acceptable form of contraception, and have a negative urine pregnancy test on admission to the treatment phase of the study. 6\. Males must agree to practice an acceptable form of contraception 7. Judged by the Investigator and/or designee to be in good health as documented by the medical history, and vital sign assessments. Exclusion Criteria: 1. Unwilling or unable to provide informed consent. 2. More than three digits absent from the hands due to congenital or accidental cause(s). 3. Reports receiving any investigational drug within 30 days prior to dosing. 4. Reports a clinically significant illness during the 30 days prior to the in-clinic portion of the study (as determined by the Investigator). 5. Reports any personal history of substance abuse (including drug/alcohol abuse or addiction) or mental illness (e.g. major depression) within one year prior to screening visit. 6. Is pregnant (females only). 7. Presence of any clinically significant results from laboratory tests and vital signs assessments, as judged by the Investigator. 8. Reports history of respiratory depression (e.g., sleep apnea). 9. Reports history of reaction to codeine (e.g., nausea, allergy). 10. Current severe hypotension (i.e., systolic blood pressure \<90 mmHg). 11. Reports known or suspected gastrointestinal obstruction including, paralytic ileus. 12. Reports current presence of acute bronchial asthma/ upper airway obstruction. 13. Reports a history of clinically significant allergies, including food or drug allergies, as judged by the Investigator. 14. Reports history or current condition of adrenal insufficiency. 15. Reports history or current condition of renal disease. 16. If, in the opinion of the Investigator, the subject is not suitable for the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Drug abuse illicit are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CenExel Clinical Research
RECRUITINGMarlton, New Jersey, 08053, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.